140 related articles for article (PubMed ID: 38794309)
1. Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters.
Kulkarni CP; Yang J; Koleske ML; Lara G; Alam K; Raw A; Rege B; Zhao L; Lu D; Zhang L; Yu LX; Lionberger RA; Giacomini KM; Kroetz DL; Yee SW
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794309
[TBL] [Abstract][Full Text] [Related]
2. Conversion of Olmesartan to Olmesartan Medoxomil, A Prodrug that Improves Intestinal Absorption, Confers Substrate Recognition by OATP2B1.
Fukazawa N; Nishimura T; Orii K; Noguchi S; Tomi M
Pharm Res; 2024 May; 41(5):849-861. PubMed ID: 38485855
[TBL] [Abstract][Full Text] [Related]
3. Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake.
Wen F; Shi M; Bian J; Zhang H; Gui C
Pharm Biol; 2016; 54(2):293-302. PubMed ID: 25858254
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
[TBL] [Abstract][Full Text] [Related]
5. pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.
Kis O; Zastre JA; Ramaswamy M; Bendayan R
J Pharmacol Exp Ther; 2010 Sep; 334(3):1009-22. PubMed ID: 20507927
[TBL] [Abstract][Full Text] [Related]
6. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions.
Shirasaka Y; Shichiri M; Mori T; Nakanishi T; Tamai I
J Pharm Sci; 2013 Sep; 102(9):3418-26. PubMed ID: 23794501
[TBL] [Abstract][Full Text] [Related]
7. Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space.
Unger MS; Mudunuru J; Schwab M; Hopf C; Drewes G; Nies AT; Zamek-Gliszczynski MJ; Reinhard FBM
Mol Pharm; 2020 Feb; 17(2):488-498. PubMed ID: 31834804
[TBL] [Abstract][Full Text] [Related]
8. Food Additives as Inhibitors of Intestinal Drug Transporter OATP2B1.
Tikkanen A; Pierrot E; Deng F; Sánchez VB; Hagström M; Koenderink JB; Kidron H
Mol Pharm; 2020 Oct; 17(10):3748-3758. PubMed ID: 32845645
[TBL] [Abstract][Full Text] [Related]
9. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
10. Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters.
Weiss J; Bajraktari-Sylejmani G; Haefeli WE
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32992777
[TBL] [Abstract][Full Text] [Related]
11. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
12. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Human ABC Efflux Transporters P-gp and BCRP by the BDE-47 Hydroxylated Metabolite 6-OH-BDE-47: Considerations for Human Exposure.
Marchitti SA; Mazur CS; Dillingham CM; Rawat S; Sharma A; Zastre J; Kenneke JF
Toxicol Sci; 2017 Jan; 155(1):270-282. PubMed ID: 28031414
[TBL] [Abstract][Full Text] [Related]
14. Intestinal absorption mechanism of rotundic acid: Involvement of P-gp and OATP2B1.
Shang H; Sun Y; Wang Z; Zhou Y; Yang H; Ci X; Cui T; Xia Y; Gu Y; Liao M; Li Q; Si D; Liu C
J Ethnopharmacol; 2022 May; 289():115006. PubMed ID: 35051604
[TBL] [Abstract][Full Text] [Related]
15. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
16. Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites.
Shirasaka Y; Mori T; Shichiri M; Nakanishi T; Tamai I
Drug Metab Pharmacokinet; 2012; 27(3):360-4. PubMed ID: 22201122
[TBL] [Abstract][Full Text] [Related]
17. Nitrofurantoin transport by placental choriocarcinoma JAr cells: involvement of BCRP, OATP2B1 and other MDR transporters.
Feinshtein V; Holcberg G; Amash A; Erez N; Rubin M; Sheiner E; Polachek H; Ben-Zvi Z
Arch Gynecol Obstet; 2010 Jun; 281(6):1037-44. PubMed ID: 19924425
[TBL] [Abstract][Full Text] [Related]
18. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
19. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
20. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
